No, Aspirin is NOT Indicated
For a patient with a CHA₂DS₂-VASc score of 0 and paroxysmal atrial fibrillation, aspirin should not be prescribed—no antithrombotic therapy is recommended. This recommendation applies regardless of whether the patient is receiving anticoagulation, as a score of 0 indicates truly low stroke risk that does not warrant any antithrombotic intervention.
Evidence-Based Rationale
The most recent and authoritative guidelines uniformly agree on this approach:
2018 CHEST Guidelines provide a strong recommendation (moderate quality evidence) that low-risk patients with CHA₂DS₂-VASc score of 0 in males or 1 in females (where the point is for female sex alone) should not be offered antithrombotic therapy to prevent stroke 1.
2014 AHA/ACC/HRS Guidelines state it is reasonable (Class IIa, Level of Evidence B) to omit antithrombotic therapy in patients with CHA₂DS₂-VASc score of 0 2. Importantly, these guidelines explicitly recommend against both oral anticoagulation and aspirin in this population 3.
Multiple international guidelines from 2020-2022 (ESC, APHRS, NICE) consistently state that "low stroke risk" patients (CHA₂DS₂-VASc 0 in men, or 1 in women where the point is sex alone) should not be offered antithrombotic therapy 4.
Why Aspirin is Specifically Contraindicated
The 2018 CHEST Guidelines make an even stronger statement: they recommend against antiplatelet therapy alone (including aspirin monotherapy) for stroke prevention in AF, regardless of stroke risk (Strong recommendation, moderate quality evidence) 1. This represents a significant evolution from older guidelines that suggested aspirin as an option for low-risk patients.
The 2014 guidelines explicitly note that in patients with CHA₂DS₂-VASc score of 0, one should not treat with OAC or with aspirin (Class IIa; Level of Evidence B) 3.
Clinical Context: Paroxysmal vs. Permanent AF
The paroxysmal nature of your patient's AF does not change this recommendation. Stroke risk is equivalent across paroxysmal, persistent, and permanent AF patterns when the CHA₂DS₂-VASc score is the same 5. The guidelines explicitly include patients with paroxysmal AF in their recommendations 1.
Common Pitfalls to Avoid
Don't confuse CHA₂DS₂-VASc score of 0 with score of 1: For males with a score of 1, guidelines suggest that no therapy, aspirin, or oral anticoagulation may be considered (Class IIb) 2. However, with a score of 0, the recommendation is clearer—no antithrombotic therapy.
Don't prescribe aspirin "just to be safe": Recent evidence shows aspirin adds bleeding risk without meaningful stroke reduction in truly low-risk AF patients. A 2026 study demonstrated that adding aspirin to anticoagulation significantly increased major bleeding (RR 3.15) without reducing ischemic events 6.
Don't apply outdated guidelines: Older recommendations (pre-2014) sometimes suggested aspirin for low-risk AF patients. Current evidence has moved decisively away from this approach.
The Bottom Line
A CHA₂DS₂-VASc score of 0 represents a genuinely low stroke risk (approximately 1% annually or less) that is comparable to age-matched populations without AF 7. In this scenario, aspirin provides no meaningful benefit while exposing the patient to bleeding risk. The appropriate management is no antithrombotic therapy, with annual reassessment of stroke risk factors as the patient ages or develops new comorbidities.